Announcement • May 21
Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026 Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026. Location: the offices of shakespeare martineau llp, c o ampa holdings llp, level 19, the shard, 32 london bridge street, se1 9sg, london United Kingdom New Risk • Apr 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£276k). Earnings have declined by 7.9% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (UK£8.52m market cap, or US$11.5m). Announcement • Apr 02
Cizzle Biotechnology Holdings Plc announced that it expects to receive £0.25 million in funding Cizzle Biotechnology Holdings Plc announced a private placement of unsecured convertible loan notes for gross proceeds of up to £250,000 on April 2, 2026. The transaction will include participation from existing investor Frazer Lang. The notes will be draw down as to £100,000 on May 1, 2026, £100,000 on June 1, 2026, and £50,000 on July 1, 2026. The notes will now be convertible at £.014 per ordinary share at any time up to October 30, 2026. No interest or fees are payable on the notes. In connection with the transaction, the company has issued warrants to Frazer Lang over 10,000,000 ordinary shares at an exercise price of £0.025, to be exercised within two years from the date of issue, bringing his total warrant holding to 22,500,000 warrants.